Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/978-3-030-79308-1_2
Reference251 articles.
1. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723.
2. Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., et al. (2020). Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC immunotherapy resistance taskforce. Journal for Immunotherapy of Cancer, 8(1), e000398.
3. Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., Rawal, B., Chen, Y. H., Catalano, P. S., et al. (2020). Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in untreated Oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial. JAMA Oncology, 6(10), 1563–1570.
4. Ling, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., et al. (2020). Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precision Oncology, 4(1), 32.
5. Schwartz, L. H., Litiere, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., et al. (2016). RECIST 1.1-update and clarification: From the RECIST committee. European Journal of Cancer, 62, 132–137.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma;Journal of Cancer Research and Clinical Oncology;2024-07-13
2. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms;Cell & Bioscience;2023-06-30
3. Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?;Journal of Personalized Medicine;2023-05-17
4. Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma;Frontiers in Immunology;2023-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3